• Profile

Autologous dendritic cell immunotherapy plus chemotherapy in metastatic castration-resistant prostate cancer

JAMA Feb 15, 2022

The efficacy and safety of DCVAC/PCa, an active cellular immunotherapy, are investigated in men with metastatic castration-resistant prostate cancer (mCRPC).

  • A randomized clinical trial of 1,182 patients.

  • Overall survival (OS) did not differ between the DCVAC/PCa and placebo groups, with median OS of 23.9 and 24.3 months, respectively.

  • Treatment-emergent adverse events occurred in 9.2% and 12.7% of patients in DCVAC/PCa and placebo arms, respectively.

  • No extension in OS occurred in correlation with receiving DCVAC/PCa combined with docetaxel plus prednisone and continuing it as maintenance treatment; patients with mCRPC well tolerated the treatment.

  • Researchers emphasize identification of factors linked with the efficacy of immunotherapy to better select patients and thus prolong OS.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen